331A Medix Inc. - Financial Results

About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.

331A

TSE Standard

Medix Inc.

499

JPY

-1

(-0.20%)

Mar 13, 1:23 pm JST

3.13

USD

Mar 13, 12:23 am EDT

Result

PTS

outside of trading hours

ー

Summary Chart Historical News Financial Result

Current Period Guidance

Annual

Result

Guidance History

Growth Rate

Profitability

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Mar, 2022 ＊	14,392	ー	516	134	18.2	3.80	ー	J-GAAP
Mar, 2023 ＊	4,273	784	815	401	53.0	6	ー	J-GAAP
Mar, 2024 ＊	4,179	801	804	489	64.9	8	ー	J-GAAP
Mar, 2025	4,161	802	951	803	106.5	14	May 13, 2025	J-GAAP
Mar, 2026 Guidance	4,201	606	610	412	54.4	15	Feb 10, 2026	J-GAAP
YoY	+1.0%	-24.4%	-35.9%	-48.7%	-49.0%

Revision Direction	Revision Date	Revenue	Operating Profit	Ordinary Profit	Net Profit	Revised Dividend	Accounting Standards
Mar, 2025	Mar 19, 2025	4,185	810	957	812	14*	J-GAAP
Results	May 13, 2025	4,161	802	951	803	14*	J-GAAP
Mar, 2026	May 13, 2025	4,387	832	832	577	15	J-GAAP
	Feb 10, 2026	4,201	606	610	412	15	J-GAAP

Fiscal Year	Revenue	YoY	Operating Profit	YoY	Ordinary Profit	YoY	Adj. EPS	YoY
Mar, 2020	15,439	－	Available in future release
Mar, 2021	11,979	-22.4
Mar, 2022	14,392	+20.1
Mar, 2023	4,273	-70.3
Mar, 2024	4,179	-2.2
Mar, 2025	4,161	-0.4
Mar, 2026 Guidance	4,201	+1.0	606	-24.4	610	-35.9	54.4	-48.9

Fiscal Year	Revenue	Operating Profit	Operating Profit Margin	ROE	ROA	Total Asset Turnover Ratio	Adj. EPS
Mar, 2024 ＊	4,179	801	19.2	25.17	8.63	0.74	64.9
Mar, 2025	4,161	802	19.3	29.60	12.77	0.66	106.5
Mar, 2026 Guidance	4,201	606	14.4	12.72	5.85	0.60	54.4

All-Time High

	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS
Record	15,439	802	951	803	106.5
Fiscal Year	Mar, 2020	Mar, 2025	Mar, 2025	Mar, 2025	Mar, 2025

Second Half

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Oct - Mar, 2024	2,217	549	551	368	48.8	14	May 13, 2025	J-GAAP
Oct - Mar, 2025 Guidance	2,264	365	370	249	32.9	15	Feb 10, 2026	J-GAAP
YoY	+2.1%	-33.5%	-32.8%	-32.3%	-32.7%

Cash Flow

Annual

Fiscal Year	Operating Profit	Fee Cash Flow	Operating Cash Flow	Investing Cash Flow	Financial Cash Flow	Cash & Equivalents	Cash Ratio	Accounting Standards
Mar, 2023	784	585	557	28	0	2,313	42.59	J-GAAP
Mar, 2024	801	683	675	8	-217	2,780	47.09	J-GAAP
Mar, 2025	802	913	499	414	76	3,771	56.55	J-GAAP

Actual Performance and Financial Trends

Accumulated Results 3rd Quarter

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Progress Rate vs. First Half	Announce	Accounting Standards
Apr - Dec, 2024	2,997	499	646	596	79.3	67.9	Mar 19, 2025	J-GAAP
Apr - Dec, 2025	2,999	455	456	310	39.6	74.8	Feb 10, 2026	J-GAAP
YoY	+0.1%	-8.8%	-29.4%	-48.0%	-50.1%

Quarterly Results

Result

Growth Rate

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Operating Profit Margin	Announce	Accounting Standards
Oct - Dec, 2024	1,053	246	246	161	21.4	23.4	Mar 19, 2025	J-GAAP
Jan - Mar, 2025	1,164	303	305	207	27.5	26.0	May 13, 2025	J-GAAP
Apr - Jun, 2025	961	77	78	53	6.7	8.0	Aug 12, 2025	J-GAAP
Jul - Sep, 2025	976	164	162	110	13.9	16.8	Nov 11, 2025	J-GAAP
Oct - Dec, 2025	1,062	214	216	147	18.8	20.2	Feb 10, 2026	J-GAAP
YoY	+0.9%	-13.0%	-12.2%	-8.7%	-12.3%

Fiscal Year	Revenue	YoY	Operating Profit	YoY	Ordinary Profit	YoY	Adj. EPS	YoY
Oct - Dec, 2024	1,053	－	Available in future release
Jan - Mar, 2025	1,164	－
Apr - Jun, 2025	961	－
Jul - Sep, 2025	976	－
Oct - Dec, 2025	1,062	+0.9	214	-13.0	216	-12.2	18.8	-12.1

All-Time High Quarterly Results

	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS
Record	1,164	303	305	207	27.5
Fiscal Year	Mar, 2025	Mar, 2025	Mar, 2025	Mar, 2025	Mar, 2025

Key Balance Sheet Figures

Fiscal Year	BPS	Equity Ratio	Total Asset	Equity	Retained Earnings	Interest-Bearing Debt Ratio	Announce	Accounting Standards
Mar, 2023	11,410.00	31.8	5,431	1,729	ー	ー	ー	J-GAAP
Mar, 2024	14,324.00	36.5	5,903	2,157	2,018	0.16	ー	J-GAAP
Mar, 2025	407.06	49.0	6,669	3,268	2,762	0.03	May 13, 2025	J-GAAP
Apr - Dec, 2025	ー	46.0	7,048	3,240	2,960	0.27	Feb 10, 2026	J-GAAP

Medix Inc.(331A) Financial Results